| 1 |
Schuchter LM, Hensley ML, Meropol, (2002) 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology, J Clin Oncol, 20:2895-2903.
DOI
ScienceOn
|
| 2 |
Steven E. Lipshultz SE, Rifai N, Dalton VM, (2004). The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. NEJM. Jul 8:145-153.
DOI
ScienceOn
|
| 3 |
Marty M, Espié M, Llombart A (2006) multicenter randomized phase III study of the cardioprotective effect of dexrazoxane(}$} "$cardioxane^{(R)}$") ) in advanced/metastastic breast cancer patients treated with anthracycline-based chemotherapy. Annals of Oncology 17:614-622
DOI
ScienceOn
|
| 4 |
Ranulfo Pinheiro de Matos Neto RP, Petrilli AS, (2006). Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane. Arq Bras Cardiol. Dec; 87:763-771.
DOI
ScienceOn
|
| 5 |
Moghrabi A, Levy DE, Asselin B, (2007). Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. Feb 1;109:896-904.
|
| 6 |
Lipshultz SE, Sanders SP, Goorin AM (1994) Monitoring for anthracycline cardiotoxicity. Pediatrics:433-437.
|
| 7 |
Lipshultz SE, Sanders SP, Goorin AM, (1994) The anthracycline cardiotoxicity debate. Pediatrics 94;781-782.
|
| 8 |
Haycock GB, Schwartz GJ, Wisotsky DH, (1978) Geometric method for measuring body surface area: A height-weight formula validated in infants, children and adults. J Pediatr 93;62-66.
DOI
|
| 9 |
Yeh, E.T, Tong, AT, Lenihan, (2009) Cardiovascular complications of cancer therapy; diagnosis, pathogenesis, and management. J Am Coll Cardiol. Jun 16; 2231-2247.
DOI
ScienceOn
|
| 10 |
Floyd, Nguyen, Lobins, (2005) Cardiotoxicity of cancer therapy; Journal Clin Oncol 23:7685.
DOI
ScienceOn
|
| 11 |
Singal, Iliskovic, PK (1998) Doxorubicin induced cardiomyopathy; NEJM 339:900-905.
DOI
ScienceOn
|
| 12 |
Von Hoff, DD, Rozencweig, M, Layard, M, (1977) Daunomycin-induced cardiotoxicity in children and adults. Am J Med 62:220
|
| 13 |
Seifert, CF, Nesser, ME, Thompson, (1994) Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 28:1063.
DOI
|
| 14 |
Sehested M, (1994) Dexrazoxane for Protection Against Cardiotoxic Effects of Anthracyclines, J Clin Oncol, 14:2884.
|
| 15 |
Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuos infusion. Ann Intern Med. 96: 133-9.
DOI
ScienceOn
|
| 16 |
Chiron BV. In (1995) Cardioxane Product Monograph. Amsterdan, The Netherlands.
|
| 17 |
Bu'Lock FA, Gabriel HM, Oakhill A (1993), Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J. Aug;70(2):185-188.
DOI
|
| 18 |
Singal, PK, Deally, CMR, Weinberg,(1987) Subcellular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol 19:817.
DOI
ScienceOn
|
webmaster
